hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== Business career == Newsom and a group of investors created the company PlumpJack Associates L.P. on May 14, 1991. The group started the PlumpJack Winery in 1992 with the financial help of his family friend Gordon Getty. PlumpJack was the name of an opera written by Getty, who invested in 10 of Newsom's 11 businesses. Getty told the San Francisco Chronicle that he treated Newsom like a son and invested in his first business venture because of that relationship. According to Getty, later business investments were because of "the success of the first". One of Newsom's early interactions with government occurred when Newsom resisted the San Francisco Department of Public Health's requirement to install a sink at his PlumpJack wine store. The Health Department argued that wine was a food and required the store to install a $2,700 sink in the carpeted wine shop on the grounds that the shop needed the sink for a mop. When Newsom was later appointed supervisor, he told the San Francisco Examiner: "That's the kind of bureaucratic malaise I'm going to be working through." The business grew to an enterprise with more than 700 employees. The PlumpJack Cafe Partners L.P. opened the PlumpJack Café, also on Fillmore Street, in 1993. Between 1993 and 2000, Newsom and his investors opened several other businesses that included the PlumpJack Squaw Valley Inn with a PlumpJack Café (1994), a winery in Napa Valley (1995), the Balboa Café Bar and Grill (1995), the PlumpJack Development Fund L.P.
The city has hosted numerous major sporting events, including the inaugural AFC Asian Cup, the 2008 Summer Olympics equestrian events, the 2009 East Asian Games, the Rugby World Cup Sevens in 1997 and 2005, the 2005 World Squash Championships and 2025 World Grand Prix (snooker). The territory regularly hosts the Hong Kong Sevens, Hong Kong Marathon, Hong Kong Open (tennis), Hong Kong Tennis Classic and LIV Golf Hong Kong. Hong Kong represents itself separately from mainland China, with its own sports teams in international competitions. The territory has participated in almost every Summer Olympics since 1952 (with the exception of its support of the 1980 Summer Olympics boycott) and has earned nine medals. Lee Lai-shan won the territory's first Olympic gold medal at the 1996 Atlanta Olympics, and Cheung Ka Long won the second one in Tokyo 2020. Hong Kong athletes have won 126 medals at the Paralympic Games and 17 at the Commonwealth Games. Although they are no longer part of the Commonwealth of Nations, the city's last appearance was in 1994.
According to the Salvadoran government, the country's homicide rate was 38 per 100,000 people in 2019; 19.7 per 100,000 in 2020; 17.6 per 100,000 in 2021; 7.8 per 100,000 in 2022; 2.4 per 100,000 in 2023; and 1.9 per 100,000 in 2024. Bukele has attributed the decline to his security policies. According to Celia Medrano, a human-rights lawyer and former general coordinator of the Commission for the Defense of Human Rights of Central America, it is "impossible" ("imposible") to verify the Salvadoran government's homicide figures because there is "no public access" ("no hay acceso público") to a daily homicide registry. Medrano stated that deaths in custody are not registered as homicides. Bodies found in mass graves, missing persons, and people killed in police encounters are not included in the government's homicide statistics. In July 2024, then former United States president Donald Trump falsely accused Bukele's government of "exporting" criminals to the United States to lower El Salvador's crime rate.
Sources: en.wikipedia.org
This stage of the aerobic system occurs on the cristae (infoldings of the membrane of the mitochondria). The reaction of each NADH in this electron transport chain provides enough energy for 3 molecules of ATP, while reaction of FADH2 yields 2 molecules of ATP. This means that 10 total NADH molecules allow the regeneration of 30 ATP, and 2 FADH2 molecules allow for 4 ATP molecules to be regenerated (in total 34 ATP from oxidative phosphorylation, plus 4 from the previous two stages, producing a total of 38 ATP in the aerobic system). NADH and FADH2 are oxidized to allow the NAD+ and FAD to be reused in the aerobic system, while electrons and hydrogen ions are accepted by oxygen to produce water, a harmless byproduct.
The total ion current chromatogram (TICC) represents the summed intensity across the entire range of masses being detected at every point in the analysis. The range is typically several hundred mass-to-charge units or more. In complex samples, the TICC often provides limited information as multiple analytes elute simultaneously, obscuring individual species.
When a hormone binds to the receptor, it results in the activation of a signal transduction pathway that typically activates gene transcription, resulting in increased expression of target proteins. Hormones can also act in non-genomic pathways that synergize with genomic effects. Water-soluble hormones (such as peptides and amines) generally act on the surface of target cells via second messengers. Lipid soluble hormones, (such as steroids) generally pass through the plasma membrane of target cells (both cytoplasmic and nuclear) to act within their nuclei. Brassinosteroids, a type of polyhydroxysteroids, are a sixth class of plant hormones and may be useful as an anticancer drug for endocrine-responsive tumors to cause apoptosis and limit plant growth. Despite being lipid soluble, they nevertheless attach to their receptor at the cell surface. In vertebrates, endocrine glands are specialized organs that secrete hormones into the endocrine signaling system. Hormone secretion occurs in response to specific biochemical signals and is often subject to negative feedback regulation. For instance, high blood sugar (serum glucose concentration) promotes insulin synthesis. Insulin then acts to reduce glucose levels and maintain homeostasis, leading to reduced insulin levels. Upon secretion, water-soluble hormones are readily transported through the circulatory system. Lipid-soluble hormones must bind to carrier plasma glycoproteins (e.g., thyroxine-binding globulin (TBG)) to form ligand-protein complexes.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.